Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor

31 Jan 2018

Abstract excerpt

Abstract Bromodomain and extra-terminal (BET) family proteins are key regulators of gene expression in cancer. Herein, we utilize BRD4 profiling to identify critical pathways involved in pathogenesis of chronic lymphocytic leukemia (CLL). BRD4 is overexpressed in CLL and is enriched proximal to genes upregulated or de novo expressed in CLL with known functions in disease pathogenesis and progression. These genes,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Protein Degradation and Inhibitors
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29386193
DOI: 10.1158/2159-8290.cd-17-0902

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 10 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET InhibitorPMID 29386193Read ↗

Molecular bases of chronic lymphocytic leukemia in light of new treatments.Semantic proximity Read ↗

A novel triple-action inhibitor targeting B-cell receptor signaling and BRD4 demonstrates preclinical activity in chronic lymphocytic leukemiaSemantic proximity Read ↗

Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemiaSemantic proximity Read ↗

BRD4 and Cancer: going beyond transcriptional regulationSemantic proximity Read ↗

Targeting BET Bromodomains for Cancer TreatmentSemantic proximity Read ↗

Bromodomain containing 4 (BRD4) as a potential prognostic marker in a pan-cancer analysis of human tumorsSemantic proximity Read ↗

Trisomy 12 chronic lymphocytic leukemia expresses a unique set of activated and targetable pathways.Semantic proximity Read ↗

B cell signalling pathways—New targets for precision medicine in chronic lymphocytic leukaemiaSemantic proximity Read ↗

SETDB2 Links E2A-PBX1 to Cell-Cycle Dysregulation in Acute Leukemia through CDKN2C RepressionSemantic proximity Read ↗

PAX5 epigenetically orchestrates CD58 transcription and modulates blinatumomab response in acute lymphoblastic leukemiaSemantic proximity Read ↗

Linking aberrant chromatin features in chronic lymphocytic leukemia to transcription factor networksSemantic proximity Read ↗

Epigenetic inactivation of DLX4 is associated with disease progression in chronic myeloid leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.